SCHEMBL1401545

SCHEMBL1401545

C[C@H](N)C(=O)Oc1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
LMNA P02545 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ELANE P08246 2/20 0.43
CYP19A1 P11511 4/20 0.39
ROCK2 O75116 3/20 0.38
ROCK1 Q13464 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
PTGS2 P35354 1/20 0.37
NPC1 O15118 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23493150 0.86 ELANE (0.55) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL15679080 0.86 ELANE (0.55) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL2625475 0.84 ELANE (0.60) HSD17B10LMNACYP1A2CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL30184762 0.84 ELANE (0.53) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL285949 0.80 ELANE (0.53) HSD17B10LMNACYP1A2ELANEALDH1A1
SCHEMBL9939655 0.80 ELANE (0.53) HSD17B10LMNACYP1A2ELANEALDH1A1
SCHEMBL133568 0.80 ELANE (0.53) HSD17B10LMNACYP1A2ELANEALDH1A1
Bromide SCHEMBL27527962 0.79 HSD17B10 (0.44) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL27540323 0.79 CYP19A1 (0.54) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL28460599 0.79 HSD17B10 (0.41) HSD17B10LMNACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4007636-B1 COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE OKYO PHARMA LTD (GG) 2024-06-19 EP claimed
US-20240174715-A1 PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS INDI MOLECULAR, INC. 2024-05-30 US claimed
US-11919972-B2 Peptide libraries with non-canonical amino acids REGENERON PHARMACEUTICALS, INC. (US) 2024-03-05 US claimed
EP-4294820-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES Ohio State Innovation Foundation (US) 2023-12-27 EP claimed
EP-4218926-A2 COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE Okyo Pharma Limited (GG) 2023-08-02 EP claimed
EP-4136102-A1 LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE I2O Therapeutics, Inc. (US) 2023-02-22 EP claimed
US-20220281915-A1 COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE OKYO PHARMA LIMITED (GG) 2022-09-08 US claimed
WO-2021212023-A1 LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE INTARCIA THERAPEUTICS, INC. (US) 2021-10-21 WO claimed
WO-2020230780-A1 Ras INHIBITORY PEPTIDE 一丸ファルコス株式会社 2020-11-19 WO claimed
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 EP disclosed
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 WO disclosed
CN-119522233-A GLP-1/GIP double agonist and preparation method and application thereof 杭州中美华东制药有限公司 2025-02-25 CN disclosed
CN-119080887-A GLP-1/GIP double agonist and preparation method and application thereof 杭州中美华东制药有限公司 2024-12-06 CN disclosed
EP-4007636-B1 COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE OKYO PHARMA LTD (GG) 2024-06-19 EP disclosed
WO-2005116643-A2 IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE CARLSBERG A/S (DK) 2005-12-08 WO disclosed
US-6858210-B1 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same LA JOLLA PHARMACEUTICAL CO. (US) 2005-02-22 US disclosed
WO-2004089297-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) 2004-10-21 WO disclosed
WO-2002100885-A2 A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME NOVASPIN BIOTECH GMBH (DE) 2002-12-19 WO disclosed
EP-0960108-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1999-12-01 EP disclosed
WO-1998033788-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1998-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281915-A1 COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE CXCL8, CCR8, IL18 HSD17B10 3772/4885LMNA 3790/4885CYP1A2 4213/4885
US-20240174715-A1 PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS ARGLU1, NGLY1, VIP HSD17B10 4662/4885LMNA 3601/4885CYP1A2 2495/4885
US-11919972-B2 Peptide libraries with non-canonical amino acids ARGLU1, NGLY1, VIP HSD17B10 4662/4885LMNA 3601/4885CYP1A2 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.